AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Study Demonstrates Positive Results for Psoriasis Patients Treating with the Clarify Home Light Therapy System

March 13, 2019

SAN DIEGO--(BUSINESS WIRE)--Mar 13, 2019--Clarify Medical today announced the publication of clinical study results using the Clarify Home Light Therapy System to treat patients with plaque psoriasis. The study demonstrated treatment efficacy, adherence, safety, and patient satisfaction using the novel connected home phototherapy system.

Eight adult patients with stable plaque psoriasis who were previously unresponsive to topical therapies completed a 10-week study using the Clarify System as a monotherapy. All patients that completed the study experienced improvement in the treated lesions, with a mean improvement of 57% in PSI (p<0.0001 compared to baseline and p<0.0002 compared to the control lesions). Control lesions did not significantly change over the treatment period (p=0.1411). At the conclusion of the study, when restrictions on combination therapy were lifted and topical corticosteroids were reintroduced, all patients reported 100% clearance within an additional 3 weeks. No adverse events or system functionality issues were reported. For those that completed the study, patient treatment adherence to the therapy was 96% and the Clarify System received five-star satisfaction scores from 100% of patients.

“This study shows strong clinical results with at-home based Narrow Band UVB phototherapy using the Clarify Medical Home Light Therapy System,” said Lawrence D. Eichenfield, M.D., Professor of Dermatology and Pediatrics and Chief of Pediatric Dermatology at University of California, San Diego and Rady Children’s Hospital, San Diego. “The novel delivery system supports the ability to deliver home phototherapy for chronic skin diseases in a user-friendly, effective method that should allow high adherence and compliance leading to positive patient outcomes.”

The Clarify System, cleared by FDA in 2017, is indicated for localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis and leukoderma on all skin types (I-VI). It is the first and only connected phototherapy system that uses an app on the patient’s own smartphone (iOS or Android) to manage the dose, frequency, and duration of UVB light therapy, helping to ensure that patients receive the proper doses recommended by the American Academy of Dermatology in its published Guidelines of care for the management of psoriasis and psoriatic arthritis. The treatment regimen is prescribed by the patient’s physician but monitored and controlled by the Clarify System, enabling patients to administer treatment with clinical precision in the convenience of their homes. The connected system monitors dosing, adherence, compliance, patient progress and satisfaction.

The Clarify smartphone app syncs to a patented, lightweight, handheld device which guides patients through delivering targeted narrowband UVB phototherapy treatments for their specific skin conditions. All treatment records, including photographs and patient-reported outcomes, are available to both the patient and the physician and can be used for evaluation during follow-up visits. Clarify CarePartners, trained patient support personnel, act as the first line of support for patients – coaching them on the use of the system and encouraging treatment adherence – greatly reducing the burden of these functions on the physician’s practice.

“This study supports what the scientific literature and clinical practice have demonstrated for decades – narrowband UVB phototherapy, as both monotherapy and as part of combination therapy regimens, is effective for the treatment of psoriasis,” said George Mahaffey, President & CEO of Clarify Medical. “The Clarify System’s patented technology and patient support function enables patients to administer treatment at home with the same level of control and care that they would receive in the clinic. We are excited to provide this novel targeted therapeutic option to patients managing psoriasis, vitiligo and other chronic skin conditions.”

Clarify Medical is a private San Diego-based medical device company focused on developing innovative technology, products and services that improve care for people with chronic skin conditions. Its Clarify Home Light Therapy System is now available nationally in the US. Learn more at  www.clarifymed.com .

View source version on businesswire.com:https://www.businesswire.com/news/home/20190313005138/en/

Media Contact: Teddy Fulham, 626-823-6744,teddy@clarifymed.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: SENIORS WOMEN TECHNOLOGY VENTURE CAPITAL SOFTWARE TELECOMMUNICATIONS HEALTH CLINICAL TRIALS MEDICAL DEVICES MOBILE/WIRELESS OTHER HEALTH PROFESSIONAL SERVICES CONSUMER FAMILY GENERAL HEALTH MEN

SOURCE: Clarify Medical

Copyright Business Wire 2019.

PUB: 03/13/2019 06:00 AM/DISC: 03/13/2019 06:01 AM

http://www.businesswire.com/news/home/20190313005138/en